Las patentes, US No. 12.215.391 y No. 12.215.392, cubren métodos de análisis automatizado de MRD y aspectos del recorrido del paciente en MRD, respectivamente. La patente de análisis ...
Current liquid biopsy assays are able to detect circulating tumor DNA (ctDNA) levels when tumor burden is high, but are not sensitive enough to detect minimal residual disease (MRD) when ctDNA ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback